Silence Therapeutics (NASDAQ:SLN) Stock Price Up 3.2%

Silence Therapeutics plc (NASDAQ:SLN - Get Free Report)'s stock price rose 3.2% on Tuesday . The stock traded as high as $21.33 and last traded at $21.33. Approximately 9,683 shares changed hands during mid-day trading, a decline of 96% from the average daily volume of 238,158 shares. The stock had previously closed at $20.66.

Wall Street Analysts Forecast Growth

SLN has been the subject of several research analyst reports. Morgan Stanley lifted their price objective on shares of Silence Therapeutics from $29.00 to $45.00 and gave the company an "overweight" rating in a research note on Thursday, March 14th. HC Wainwright reiterated a "buy" rating and issued a $75.00 price objective on shares of Silence Therapeutics in a research note on Friday, March 15th. BMO Capital Markets began coverage on shares of Silence Therapeutics in a research note on Wednesday, January 31st. They issued an "outperform" rating and a $67.00 price objective for the company. Finally, Chardan Capital lifted their price target on shares of Silence Therapeutics from $26.00 to $42.00 and gave the company a "buy" rating in a research report on Thursday, March 14th.

Silence Therapeutics Trading Up 2.9 %

The firm's 50-day moving average is $22.99 and its 200-day moving average is $16.81. The company has a current ratio of 4.56, a quick ratio of 4.56 and a debt-to-equity ratio of 0.01. The firm has a market cap of $636.01 million, a price-to-earnings ratio of -14.42 and a beta of 1.41.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last posted its quarterly earnings results on Wednesday, March 13th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.22). Silence Therapeutics had a negative net margin of 171.41% and a negative return on equity of 262.17%. The business had revenue of $2.61 million during the quarter, compared to analyst estimates of $11.46 million. As a group, sell-side analysts anticipate that Silence Therapeutics plc will post -1.38 EPS for the current fiscal year.

Hedge Funds Weigh In On Silence Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Parkman Healthcare Partners LLC boosted its holdings in Silence Therapeutics by 20.8% during the 4th quarter. Parkman Healthcare Partners LLC now owns 232,942 shares of the company's stock worth $4,046,000 after acquiring an additional 40,063 shares during the last quarter. Citadel Advisors LLC bought a new stake in shares of Silence Therapeutics during the 4th quarter worth $378,000. UBS Group AG raised its stake in shares of Silence Therapeutics by 1.2% during the 4th quarter. UBS Group AG now owns 69,946 shares of the company's stock worth $1,215,000 after purchasing an additional 833 shares during the period. Vivo Capital LLC bought a new stake in shares of Silence Therapeutics during the 4th quarter worth $8,862,000. Finally, SG Americas Securities LLC bought a new stake in shares of Silence Therapeutics during the 4th quarter worth $110,000. 98.73% of the stock is owned by hedge funds and other institutional investors.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.